Duke Cancer Institute - Academic Profile

Publications

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Chronic Myelogenous Leukemia, Version 1.2015

Susan O’Brien , Jerald P. Radich , Camille N. Abboud +20 more

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase)...

2014 Journal of the National Comprehensive... 71 citations

Affiliated Researchers

Joseph O. Moore

Duke Cancer Institute

April K.S. Salama

Duke Cancer Institute

Institution Info

Type: healthcare
Country: N/A
Publications: 2
Citations: 1,599

External Links

Identifiers

ROR: https://ror.org/04vt65461